Summit Therapeutics

182 articles about Summit Therapeutics

• Summit Therapeutics Announces Underwritten Public Offering Of 1,459,000 ADSs To Raise USD17.5 Million Before Expenses

  9/14/2017

• Summit Therapeutics Announces Proposed Public Offering Of $15.0 Million Of American Depositary Shares

  9/14/2017

• Summit Therapeutics Announces Pricing Of Public Offering Of 1,459,000 American Depositary Shares

  9/14/2017

• Summit Therapeutics: Positive Top-Line Phase II Results

  9/5/2017

• Summit Therapeutics Announces Positive Top-Line Data From An Exploratory Phase II Clinical Trial Supporting Ridinilazole As A Highly Selective Antibiotic For The Treatment Of CDI

  9/5/2017

• Summit Therapeutics: Half-Yearly Report

  8/31/2017

• Summit Therapeutics Reports Financial Results For The Second Quarter And Half Year Ended 31 July 2017 And Operational Progress

  8/31/2017

• Summit Therapeutics To Report Financial Results For The Second Quarter And Half Year Ended 31 July 2017 On 31 August 2017

  8/25/2017

• Summit Therapeutics : Notice Of Results

  8/25/2017

• Summit Therapeutics : Total Voting Rights

  7/31/2017

• Summit Therapeutics: Grant Of Share Options and Restricted Stock Units

  7/19/2017

• Summit Therapeutics: Result Of AGM

  7/18/2017

• Summit Therapeutics: Exercise Of Share Options

  6/28/2017

• Summit Therapeutics Presents Data From Phase I Clinical Programme Of Ezutromid At The EPNS Congress

  6/22/2017

• Summit Therapeutics: 1st Quarter Results

  6/14/2017

• Summit Therapeutics Presents Positive New Preclinical Data On Novel CDI Antibiotic Ridinilazole At ASM Microbe 2017

  6/5/2017

• Summit Therapeutics Announces Key Appointments To Strengthen Research And Development Team

  5/23/2017

• Summit Therapeutics Completes Enrollment Of Phaseout DMD, A Phase II Clinical Trial Of Ezutromid In Patients With DMD

  5/15/2017

• Summit Therapeutics: Phase II CoDIFy Trial Results Published In Lancet Infectious Diseases

  5/2/2017

• Phase II CoDIFy Trial Results Published In Lancet Infectious Diseases With Data Showing Summit Therapeutics’s Ridinilazole Achieved Statistical Superiority Over Vancomycin In The Treatment Of C. Difficile Infection

  5/2/2017